Novel combination chemotherapy for HIV-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Novel combination chemotherapy for HIV-related non-Hodgkin's lymphoma (HIV-NHL) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A13 1994. Unique Identifier : AIDSLINE ICDB/94600010
Sawka C; Shepherd F; Brandwein J; Berinstein N; Singer J; Canadian HIV Trials Network, Vancouver, Canada

Abstract: Conventional-dose chemotherapy is poorly tolerated in HIV-NHL; even low-dose programs including our half-dose weekly drug program (Leukemia and Lymphoma 1992, 8:213-220) have been associated with significant febrile neutropenia rates. We designed a novel chemotherapy program to attempt to reduce this complication while maintaining efficacy. The program consisted of six 21 day cycles of: etoposide 50 mg po od d1-14, vincristine 2 mg iv d1, prednisone 100 mg po d 1-4, ara-c 50 mg IT d1. Mitoxantrone 6 mg/m2 was given iv d1 on cycles 1,3,5; cyclophosphamide 300 mg/m2 was given iv d1 on cycles 2,4,6. Septra or aerosol pentamidine was given throughout treatment and anti-retrovirals were started at
Keywords: Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Cytarabine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Dose-Response Relationship, Drug Drug Administration Schedule Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human Lymphoma, AIDS-Related/*DRUG THERAPY/MORTALITY Male Mitoxantrone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Prednisone/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Survival Rate Vincristine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS ABSTRACT

KWDadultantineoplasticagents,combined/adverseeffects/
940930
M9491056

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .